8月5日，吉利德科学盘中下跌3.03%，报131.15美元/股，成交额5.23亿美元。
消息面上，公司于8月4日盘后公布第二季度业绩，营收78亿美元同比增长10%，调整后每股亏损6.75美元，均优于市场预期。然而，近期收购产生的每股9.08美元知识产权研发及税务费用使公司由盈转亏。此外，新冠药物Veklury销售额暴跌81%至2300万美元，全年预测从约6亿美元腰斩至约3亿美元。高管还透露，ACA税收补贴取消导致部分患者失去医保覆盖，Q2艾滋病治疗市场趋软。尽管公司上调全年亏损指引至每股0.30-0.65美元（优于此前0.65-1.05美元），且HIV业务增长预期提升至9%-10%，但巨额一次性费用及市场疲软信号仍令投资者承压。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.